ADMA Biologics Community

11-NOV-2024 Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25) Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9, P/E24 = 44.6, P/S25 = 11.5 and P/E25 = 32.4) My assumptions: ADMA will be highly profitable due to high ratio of hyperimmunes (maybe eventually they will only manufacture hyperimmunes if S. pneumonia is successful and provided they can source the required amount of hyperimmune plasma).Read more

Key Takeaways Adoption of manufacturing improvements, capacity expansions, and new products is driving margin growth, revenue diversification, and improved supply chain resilience. Enhanced liquidity from refinancing and strong market demand underpins strategic growth initiatives and positions the company for sustained earnings improvement.Read more

Key Takeaways Heavy reliance on plasma-derived products and a concentrated portfolio exposes the company to emerging therapies, regulatory risks, and market volatility. Increasing competition, regulatory scrutiny, and rising operational expenses may restrict market share growth, compress margins, and hinder long-term financial performance.Read more

Key Takeaways Enhanced production processes and expanded plasma supply position the company for faster revenue growth and margin improvements beyond current market expectations. Strong demand drivers, strategic investments, and financial flexibility support sustained market share gains and shareholder returns.Read more